DiaMedica Therapeutics is a clinical-stage biopharmaceutical company that is developing innovative treatments where there is significant unmet clinical need or where no current therapies are available with a focus on neurological and kidney diseases. The Company is developing DM199, a recombinant (synthetic) human protein, for patients suffering from neurological and kidney diseases. DM199 has undergone clinical testing that d...
DiaMedica Therapeutics is a clinical-stage biopharmaceutical company that is developing innovative treatments where there is significant unmet clinical need or where no current therapies are available with a focus on neurological and kidney diseases. The Company is developing DM199, a recombinant (synthetic) human protein, for patients suffering from neurological and kidney diseases. DM199 has undergone clinical testing that demonstrates its exceptional safety as a potential treatment for a variety of disorders. The Company is positing DM199 for the treatment of diabetic nephropathy and post-insult treatment from acute ischemic stroke (AIS).
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.